Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ly-2584702. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 known ✓ | P23443 | 20/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 1.00 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 1.00 |
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 1.00 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 1.00 |
| ▸ | AKT1 | P31749 | 11/20 | 0.69 |
| ▸ | AKT2 | P31751 | 4/20 | 0.68 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ly-2584702 SCHEMBL311369 | 0.99 | RPS6KB1 (1.00) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Ly-2584702 SCHEMBL29493101 | 0.99 | RPS6KB1 (1.00) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| SCHEMBL803893 | 0.91 | RPS6KB1 (0.85) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Hydrochloric Acid SCHEMBL15732561 | 0.91 | RPS6KB1 (0.83) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Ly-2584702 SCHEMBL29686398 | 0.90 | RPS6KB1 (1.00) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Ly-2584702 SCHEMBL311653 | 0.90 | RPS6KB1 (1.00) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Hydrochloric Acid SCHEMBL15732485 | 0.89 | RPS6KB1 (0.79) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Hydrochloric Acid SCHEMBL15732666 | 0.89 | RPS6KB1 (0.79) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| Hydrochloric Acid SCHEMBL15732628 | 0.88 | RPS6KB1 (0.78) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 | |
| SCHEMBL3726131 | 0.86 | RPS6KB1 (0.77) | RPS6KB1RPS6KA5RPS6KA4RPS6KA3RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8334293-B2 | P70 S6 kinase inhibitor and EGFR inhibitor combination therapy | ELI LILLY AND COMPANY (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110212977-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110207752-A1 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212977-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | MTOR, RPS6KA1, RPS6KA4 | RPS6KB1 8/4885RPS6KA5 10/4885RPS6KA4 3/4885 |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | RPS6KB1 6/4885RPS6KA5 5/4885RPS6KA4 8/4885 |
| US-20110207752-A1 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | RPS6KA1, RPS6KA3, RPS6KA4 | RPS6KB1 6/4885RPS6KA5 7/4885RPS6KA4 3/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | RPS6KB1 6/4885RPS6KA5 5/4885RPS6KA4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.